Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15941059 | 0.85 | GAA (0.55) | GAAHPGDSALKBH2GRM4NPC1 | |
| SCHEMBL26365549 | 0.83 | TSHR (0.45) | GAAGRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10183504 | 0.83 | KIF11 (0.42) | GAAGRM4 | |
| SCHEMBL3606688 | 0.82 | GAA (0.55) | GAAHPGDSALKBH2GRM4NPC1 | |
| SCHEMBL10183505 | 0.82 | CYP2A6 (0.49) | GRM4NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL19625440 | 0.81 | MAP4K4 (0.43) | NPC1RAB9ADRD2DRD4DRD3 | |
| SCHEMBL13657996 | 0.81 | GRM4 (0.40) | GAAGRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13657993 | 0.80 | NOTUM (0.44) | NPC1RAB9AKDM5BEPHX2ACLY | |
| SCHEMBL26054257 | 0.80 | NPC1 (0.47) | GRM4NPC1RAB9AEPHX2 | |
| SCHEMBL28342606 | 0.79 | NOTUM (0.48) | GAAGRM4NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC | 2023-04-27 | — | — | US | disclosed |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-11-12 | — | — | US | disclosed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8987314-B2 | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-8901142-B2 | Fused tricyclic compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140171456-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-13 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171456-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | GAA 3549/4885HPGDS 1378/4885ALKBH2 4021/4885 |
| US-20140045811-A1 | AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LIPE, CEL | GAA 44/4885HPGDS 1203/4885ALKBH2 2824/4885 |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | GAA 4553/4885HPGDS 1135/4885ALKBH2 444/4885 |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | GAA 4553/4885HPGDS 1135/4885ALKBH2 444/4885 |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GAA 1958/4885HPGDS 1726/4885ALKBH2 4492/4885 |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | IL2, MALT1, FCGRT | GAA 3406/4885HPGDS 958/4885ALKBH2 776/4885 |
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | GAA 400/4885HPGDS 914/4885ALKBH2 60/4885 |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | GAA 3203/4885HPGDS 3172/4885ALKBH2 3224/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | GAA 939/4885HPGDS 1743/4885ALKBH2 3246/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | GAA 400/4885HPGDS 914/4885ALKBH2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.